id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-1234-0006,FDA,FDA-2014-E-1234,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-11-16T05:00:00Z,2016,11,2016-11-16T05:00:00Z,,2016-11-16T17:12:55Z,,0,0,0900006482399cca
FDA-2014-E-1234-0005,FDA,FDA-2014-E-1234,"Determination of Regulatory Review Period for Purposes of Patent
Extension; INVOKANA",Notice,Determinations,2016-03-01T05:00:00Z,2016,3,2016-03-01T05:00:00Z,2016-05-03T03:59:59Z,2016-03-01T14:31:22Z,2016-04369,0,0,0900006481e95106